CompletedEUCTR 2006-003805-19

An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredut...

This historical record does not confirm current site availability.

Historical research recordMultiple countriesAnxiety

The study in practice

Understand this study

What did researchers investigate?

This EU register entry describes an interventional medicine trial, designed to assign participants a study treatment. The protocol sets out the treatment, eligibility criteria and assessments. Check the source details below for country statuses and any transfer to CTIS.

Listed locations: Belgium · Finland and 2 more locations
Study phase: Phase 3

Study clarity

Study information

Study start dateNot clearly listed

Recruitment status: Completed
Enrollment listed in the registry: 360
Sponsor: sanofi-aventis recherche et développement
Sponsor type: Unknown or unclear
Study type: Drug
Intervention type: Medication / drug
Study phase: Phase 3
Locations: Belgium, Finland, Italy, ...
Age range: Not clearly listed
Official registry ID: EUCTR 2006-003805-19
Official title: Show the full official title
An eight-week, multinational, multicenter, randomized, double-blind, placebo-controlled study, with escitalopram as an active control, to evaluate the efficacy, safety and tolerability of a saredut...

Looking for a study you can join?

Explore recruiting studies

Get this study by email

Recruitment & locations

Completed

Belgium · Finland · Italy

1 more locations

Sweden

Registry details

Historical country statuses

Belgium — Completed
Finland — Completed
Italy — Completed
Sweden — Completed

FAQ

Questions about this study

Who is behind this study?

The study sponsor is sanofi-aventis recherche et développement.

Want to explore more studies?

Explore studies